Assert-IQ vs Reveal LINQ Insertable Cardiac Monitor

Direct competitors — feature-level head-to-head below. Comparability 95/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Assert-IQ

by Abbott Medical

Reveal LINQ Insertable Cardiac Monitor

by Medtronic

AI Verdict

These two tools are direct competitors, both offering insertable cardiac monitors for long-term arrhythmia detection and management. While both leverage AI for advanced detection, the Medtronic Reveal LINQ II specifically highlights its AccuRhythm™ AI for reducing false alerts and explicitly states MRI compatibility. The Abbott Assert-IQ emphasizes a slightly longer battery life of up to 6 years.

Choose Assert-IQ if…

Choose Assert-IQ if your cardiology practice or health system prioritizes the absolute longest-term continuous monitoring, up to six years, for a broad spectrum of suspected heart rhythm disorders. This system is ideal for comprehensive arrhythmia detection and proactive clinician alerts, ensuring extensive data collection and timely intervention.

View Assert-IQ →

Choose Reveal LINQ Insertable Cardiac Monitor if…

Choose Reveal LINQ II if minimizing false alerts, particularly for atrial fibrillation and pauses, is a critical concern for your patient population. Its AccuRhythm AI algorithms enhance diagnostic yield and reduce unnecessary interventions, while its MRI compatibility offers an important advantage for patients who may require future imaging.

View Reveal LINQ Insertable Cardiac Monitor →

When choosing between the Assert-IQ™ Insertable Cardiac Monitor (ICM) system from Abbott Medical and the Reveal LINQ II™ Insertable Cardiac Monitor from Medtronic, physicians should consider their primary needs for arrhythmia detection and data management. Assert-IQ™ excels in providing long-term, continuous monitoring for up to six years, coupled with advanced arrhythmia detection algorithms and proactive clinician alerts. Its secure, cloud-based data platform and remote monitoring capabilities are well-suited for large health systems and cardiology clinics prioritizing comprehensive, extended surveillance and direct clinician notification.

The key practical difference lies in their AI application and battery longevity. Reveal LINQ II™, with its AccuRhythm™ AI algorithms, focuses on enhancing diagnostic yield by significantly reducing false alerts, particularly for atrial fibrillation and pauses. This can streamline data review and potentially reduce clinician burden. While Assert-IQ™ offers a longer monitoring duration, Reveal LINQ II™ provides a nominal 4.5-year battery life and features remote programming capabilities, along with MRI compatibility. Physicians prioritizing highly accurate, AI-filtered data to minimize false positives and optimize diagnostic efficiency, especially in settings where reducing alert fatigue is critical, may find Reveal LINQ II™ more aligned with their needs. Conversely, those seeking the absolute longest monitoring duration and a robust system for proactive alerts across a broad patient base might lean towards Assert-IQ™.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Assert-IQ	Reveal LINQ Insertable Cardiac Monitor
Pricing	Enterprise	Contact vendor
Deployment	Hybrid	Implantable device with data transmitted to a cloud-based platform (CareLink™ network) via patient smartphone app or home communicator.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Assert-IQ

Tool A (Assert-IQ) offers the 'myMerlin Mobile App' for automatic data transmission and symptom logging, supported by a dedicated 'SyncUP Remote Monitoring Support' team to assist patients with setup and connectivity. While Tool B (Reveal LINQ) also has a patient app, user reviews indicate potential issues with its reliability, such as the app randomly malfunctioning or not displaying recorded data to the user, suggesting a less consistent patient experience.

Clinical Value

Assert-IQ

Both tools offer significant clinical value through AI-driven false alert reduction. However, Tool A (Assert-IQ) claims a higher reduction in false positives for AF and Pause episodes (98.7%) while maintaining high sensitivity (97.7% of true events). Additionally, Assert-IQ boasts a longer battery life of up to 6 years, compared to Reveal LINQ's 4.5 years, providing extended continuous monitoring.

Pricing & Value

Tie

Both Assert-IQ and Reveal LINQ are advanced medical devices with non-transparent, enterprise-level pricing that requires direct contact with the respective vendors. Neither tool offers a free trial. Without specific pricing information or comparative cost-effectiveness studies, it is not possible to definitively determine a winner in this dimension.

Enterprise Readiness

Tie

Both tools are developed by major, established medical device manufacturers (Abbott and Medtronic) and are designed for deployment in large health systems, hospitals, and cardiology clinics. Both are HIPAA compliant, and Tool B explicitly mentions having a Business Associate Agreement (BAA), which is implied by Tool A's HIPAA compliance. Both also offer remote programming capabilities for clinicians, indicating strong enterprise-level functionality.

Innovation

Assert-IQ

While both tools leverage AI for false alert reduction, Tool A (Assert-IQ) distinguishes itself by combining its advanced AI algorithms with the industry's longest-lasting Bluetoothu00ae ICM (up to 6 years) and 'IQ Insights' for holistic patient management. This broader integration of AI with extended monitoring capabilities and intelligent diagnostics provides a slightly more comprehensive innovative offering compared to Tool B's primary focus on its AccuRhythmu2122 AI for false alert reduction.

Support & Docs

Tie

Both Abbott and Medtronic, as leading medical device companies, provide extensive support and documentation for their ICM systems. Tool A offers clinician and patient manuals, including specific guides for its mobile app, and dedicated remote monitoring support. Tool B also provides comprehensive product and technical support, patient services, and educational materials. Given the robust offerings from both, they are equally matched in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Assert-IQ	Reveal LINQ Insertable Cardiac Monitor
Product Name	Assert-IQ	Reveal LINQ Insertable Cardiac Monitor
Company	Abbott Medical	Medtronic
Mobile App	none	MyCareLink Heartu2122 mobile app for patient data transmission
AI Algorithms	Advanced arrhythmia detection algorithms	AccuRhythmu2122 AI algorithms for reduced false alerts (AF and Pause)
Battery Longevity	up to 6 years	4.5-year battery longevity (nominal settings)
Data Export	yes	Not specified

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and Reveal LINQ Insertable Cardiac Monitor.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the maximum monitoring duration offered by each insertable cardiac monitor?

The Assert-IQu2122 Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring for up to 6 years. The Medtronic LINQ IIu2122 ICM offers a 4.5-year battery longevity with nominal settings.

How do the AI capabilities of each device compare, especially regarding false alerts?

The Reveal LINQ IIu2122 ICM utilizes AccuRhythmu2122 AI algorithms that apply deep learning to reduce false alerts for conditions like atrial fibrillation (AF) and pause. The Assert-IQu2122 ICM also features advanced AI algorithms designed to reduce false positives from AF and Pause episodes while maintaining high sensitivity.

What are the primary methods for patient data transmission and are there patient-facing mobile applications for each device?

The Reveal LINQ IIu2122 ICM transmits data to a cloud-based platform (CareLinku2122 network) via the MyCareLink Heartu2122 mobile app or MyCareLink Relayu2122 home communicator. The Assert-IQu2122 ICM uses Bluetoothu00ae Low Energy data transmission, connecting to a transmitter, often the patient's own cell phone, and utilizes the myMerlinu2122 Mobile App for data transfer to the Merlin.netu2122 Patient Care Network.

Is either device compatible with MRI scans?

The Reveal LINQ IIu2122 ICM is MRI compatible at u2264 3T with no post-insertion waiting. The Assert-IQu2122 ICM is 1.5 Tesla (T) and 3T MR Conditional.

Are there differences in the clinical specialties each device is intended for?

Assert-IQu2122 is indicated for Cardiology and Internal Medicine specialties. Reveal LINQ IIu2122 is indicated for Cardiology and Pediatrics specialties, specifically for pediatric patients who are at least 2 years old.

Does either device offer direct data export capabilities?

Assert-IQu2122 explicitly states that data export is available. While Reveal LINQ IIu2122 transmits data to the CareLinku2122 network for clinician access, direct data export as a specific feature is not explicitly detailed in the provided information.